Investor & News Press Releases Elizabeth Campbell 6/6/22 Elizabeth Campbell 6/6/22 NewAmsterdam Pharma Shares New Data from Phase 2b ROSE Study Showing up to 82.5% of Patients with Dyslipidemia Attained LDL-c Goals Read More Elizabeth Campbell 5/19/22 Elizabeth Campbell 5/19/22 NewAmsterdam Pharma to Present at Upcoming Medical Conferences New Post-Hoc Analyses from Phase 2 ROSE Trial of Obicetrapib in Patients with Dyslipidemia Read More Elizabeth Campbell 5/11/22 Elizabeth Campbell 5/11/22 New Meta-Analysis in European Heart Journal’s Cardiovascular Pharmacotherapy Examines Cholesterol Ester Transfer Protein (CETP) Inhibitors’ Role in Reduction of Diabetes Risk Read More Elizabeth Campbell 4/5/22 Elizabeth Campbell 4/5/22 NewAmsterdam Pharma Doses First Patient in Phase 2 Trial of Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy Read More Elizabeth Campbell 3/1/22 Elizabeth Campbell 3/1/22 NewAmsterdam Pharma Doses First Patient in PREVAIL, the Cardiovascular Outcomes Trial of Obicetrapib in Adults with Atherosclerotic Cardiovascular Disease (ASCVD) Read More Elizabeth Campbell 2/14/22 Elizabeth Campbell 2/14/22 New Review Article in ESC’s Cardiovascular Research Examines Cholesteryl Ester Transfer Protein (CETP) Inhibition’s Role in Reducing Cardiovascular Disease Risk Read More Newer Posts Older Posts
Elizabeth Campbell 6/6/22 Elizabeth Campbell 6/6/22 NewAmsterdam Pharma Shares New Data from Phase 2b ROSE Study Showing up to 82.5% of Patients with Dyslipidemia Attained LDL-c Goals Read More
Elizabeth Campbell 5/19/22 Elizabeth Campbell 5/19/22 NewAmsterdam Pharma to Present at Upcoming Medical Conferences New Post-Hoc Analyses from Phase 2 ROSE Trial of Obicetrapib in Patients with Dyslipidemia Read More
Elizabeth Campbell 5/11/22 Elizabeth Campbell 5/11/22 New Meta-Analysis in European Heart Journal’s Cardiovascular Pharmacotherapy Examines Cholesterol Ester Transfer Protein (CETP) Inhibitors’ Role in Reduction of Diabetes Risk Read More
Elizabeth Campbell 4/5/22 Elizabeth Campbell 4/5/22 NewAmsterdam Pharma Doses First Patient in Phase 2 Trial of Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy Read More
Elizabeth Campbell 3/1/22 Elizabeth Campbell 3/1/22 NewAmsterdam Pharma Doses First Patient in PREVAIL, the Cardiovascular Outcomes Trial of Obicetrapib in Adults with Atherosclerotic Cardiovascular Disease (ASCVD) Read More
Elizabeth Campbell 2/14/22 Elizabeth Campbell 2/14/22 New Review Article in ESC’s Cardiovascular Research Examines Cholesteryl Ester Transfer Protein (CETP) Inhibition’s Role in Reducing Cardiovascular Disease Risk Read More